Abstracts

P1073: Immune Reconstitution Inflammatory Syndrome – Wide Spectrum and Severity in Children

Background: The Immune Reconstitution Inflammatory Syndrome (IRIS) is well described after initiating antiretroviral therapy (ART) in severely immunocompromised patients. It is classified as “paradoxical” when symptoms or signs of a known co-morbidity increase or re-appear and “unmasking” with recognition of a previously unsuspected condition. There are few prospective studies of IRIS in children. Methodology: P1073…

Growth Recovery Among HIV+ Children Randomized to Lopinavir/Ritonavir or NNRTI-Based Therapy

Background: HIV-infected African children suffer high rates of wasting and short stature. Growth generally improves with the initiation of antiretroviral therapy (ART), but some studies have suggested poorer outcomes with the use of lopinavir/ritonavir (LPV/r). We compared the recovery of weight and height in a rural cohort of HIV-infected children randomized to initiate LPV/r- or…

Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Elvitegravir

Background: Safe and effective pediatric antiretroviral therapies are needed. Elvitegravir (EVG) is a once-daily integrase inhibitor in regulatory review for treatment of HIV-1 infection when coadministered with a pharmacoenhancer. This study evaluated the pharmacokinetics (PK) of ritonavir (RTV)-boosted EVG administered as the pediatric EVG tablet or suspension formulation (test) vs the adult EVG 150 mg…

Dolutegravir Regimen Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 96-Wk Data

Background: At the primary 48-Week analysis, Dolutegravir (DTG) 50 mg + abacavir (ABC)/lamivudine (3TC) once daily was superior to Tenofovir (TDF)/Emtricitabine (FTC) /Efavirenz (EFV) in treatment-naive HIV-1 patients, with 88% vs. 81% suppressed virologically (plasma HIV 100,000 c/mL) and CD4 cell count (≤ vs > 200 cells/mm3). Results: 833 subjects were enrolled and treated (84%…

First-line Therapy with LPV/r vs NVP and 2 NRTIs in a Developing Country: W144 of a Randomized Trial

Background: In resource-limited countries, NNRTI-based regimen, as recommended by WHO, may result in emergence of more HIV drug resistance, because of a low genetic barrier.The purpose of the trial is to compare the efficacy and tolerance of LPV/r and NVP-based regimens and 2 WHO nucleoside backbones in naive HIV infected patients (p.). Methodology: Naive p.…

Randomized Comparison of Anthropometric Outcomes on EFV-Based Antiretroviral Therapies

Background: ACTG A5175/PEARLS was a randomized trial undertaken in diverse geographic settings that showed similar outcomes for the primary endpoint of time to virologic failure, new AIDS event or death in the comparison of tenofovir/emtricitabine or zidovudine/lamivudine with efavirenz (TDF/ FTC+EFV or ZDV/3TC+EFV). We present results for a secondary objective comparing the effects of these…